ERBB2 and breast carcinoma: Moreover, to date, abemaciclib is the first FDA-approved CDK4 & 6i approved for the adjuvant treatment of HR+, HER2–, node-positive, early breast cancer (EBC) at high risk of recurrence and a Ki-67 score ≥20% [10, 11].